Business
Lakewood-Amedex Biotherapeutics Appoints Joseph Tucker, Ph.D., to Board of Directors
Lakewood-Amedex Biotherapeutics Inc., (NASDAQ: LABT), a clinical-stage biotechnology company advancing a novel class of potent, fast-acting, broad-spectrum antimicrobials for infectious diseases called the Bisphosphocin® class, today announced the appointment of Joseph Tucker, Ph.D., Chief Executive Officer of Enveric Biosciences (Nasdaq: ENVB), to its Board of Directors. Dr. Tucker's appointment follows Lakewood-Amedex Biotherapeutics' recent direct listing on Nasdaq and represents a key step i
About this update from Enveric Biosciences, Inc.
[{"type":"text","content":"Appointment strengthens Board with seasoned public company biotech executive following recent Nasdaq direct listing","length":115,"tagName":"p"},{"type":"text","content":"SARASOTA, Fla., April 28, 2026 /PRNewswire/ -- Lakewood-Amedex Biotherapeutics Inc., (NASDAQ: LABT), a clinical-stage biotechnology company advancing a novel class of potent, fast-acting, broad-spectrum antimicrobials for infectious diseases called the Bisphosphocin® class, today announced the appointment of Joseph Tucker, Ph.D., Chief Executive Officer of Enveric Biosciences (Nasdaq: ENVB), to its Board of Directors. Dr. Tucker's appointment follows Lakewood-Amedex Biotherapeutics' recent direct listing on Nasdaq and represents a key step in strengthening the Company's governance and strategic capabilities as it advances its growth strategy.","length":667,"tagName":"p"},{"type":"image","alt":"Lakewood-Amedex (PRNewsfoto/Lakewood-Amedex Inc.)","displaySize":"","headline":null,"caption":"Lakewood-Amedex (PRNewsfoto/Lakewood-Amedex Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":265,"url":"https://media.zenfs.com/en/prnewswire.com/b1bd157504c747429b746b6e63dbd6b9"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/QxkJZrpzBaiGRlRqsPHFaw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTQ2Nw--/https://media.zenfs.com/en/prnewswire.com/b1bd157504c747429b746b6e63dbd6b9","width":400,"height":265}},"href":"https://mma.prnewswire.com/media/2618352/Lakewood_Amedex_v2_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"Dr. Tucker is a veteran biotechnology executive with more than two decades of leadership experience spanning public and private companies and discovery to late-stage drug development. He currently serves as Chief Executive Officer and Director of Enveric Biosciences, a biotechnology company focused on advancing a pipeline of next-generation neuroplastogenic small-molecule therapeutics designed to address neuropsychiatric and neurological disorders.","length":452,"tagName":"p"},{"type":"text","content":""Joe brings a rare combination of public company leadership, capital markets expertise, and deep drug development experience," said Kelvin Cooper, Ph.D., Chief Executive Officer of Lakewood-Amedex Biotherapeutics. "His track record of building and advancing biotechnology co...